Lyell Immunopharma, Inc. Financing Cash Flow
Lyell Immunopharma, Inc. (LYEL) reported Financing Cash Flow of $52.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Lyell Immunopharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $522.00K, a 185.25% increase year-over-year.
- Lyell Immunopharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $51.72M, a 5172100.00% increase year-over-year.
- Lyell Immunopharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $222.00K, a 49.20% decline year-over-year.
- Lyell Immunopharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $50.00M.
- Lyell Immunopharma, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $50.41M, a 3701.36% increase from fiscal 2024.
- Lyell Immunopharma, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $1.33M, a 23.92% decline from fiscal 2023.
- Lyell Immunopharma, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $1.74M, a 83.61% decline from fiscal 2022.
- Lyell Immunopharma, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $10.63M, a 97.35% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $522.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $52.24M 10-Q · filed 2026-08-06 | $52.47M derived: sum of 3 quarters · filed 2026-08-06 | $102.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $51.72M 10-Q · filed 2026-05-06 | $51.94M derived: sum of 2 quarters · filed 2026-05-06 | $101.94M derived: sum of 3 quarters · filed 2026-05-06 | $102.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $222.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $50.22M derived: sum of 2 quarters · filed 2026-03-12 | $50.41M derived: sum of 3 quarters · filed 2026-08-06 | $50.41M 10-K · filed 2026-03-12 |
| 2025-09-30 | $50.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $50.18M derived: sum of 2 quarters · filed 2026-08-06 | $50.18M 10-Q · filed 2025-11-12 | $50.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $183.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $184.00K 10-Q · filed 2026-08-06 | $621.00K derived: sum of 3 quarters · filed 2026-08-06 | $621.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.00K 10-Q · filed 2026-05-06 | $438.00K derived: sum of 2 quarters · filed 2026-05-06 | $438.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.30M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $437.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $437.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.30M derived: sum of 3 quarters · filed 2026-03-12 | $1.33M 10-K · filed 2026-03-12 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $862.00K derived: sum of 2 quarters · filed 2025-11-12 | $889.00K 10-Q · filed 2025-11-12 | $1.65M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $862.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $889.00K 10-Q · filed 2025-08-12 | $1.65M derived: sum of 3 quarters · filed 2026-03-12 | $1.50M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $27.00K 10-Q · filed 2025-05-13 | $786.00K derived: sum of 2 quarters · filed 2026-03-12 | $643.00K derived: sum of 3 quarters · filed 2026-03-12 | $1.84M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $759.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $616.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.81M derived: sum of 3 quarters · filed 2026-03-12 | $1.74M 10-K · filed 2026-03-12 |
| 2023-09-30 | -$143.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.05M derived: sum of 2 quarters · filed 2024-11-07 | $984.00K 10-Q · filed 2024-11-07 | $1.85M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.13M 10-Q · filed 2024-08-07 | $1.99M derived: sum of 3 quarters · filed 2025-03-11 | $6.75M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | -$69.00K 10-Q · filed 2024-05-06 | $794.00K derived: sum of 2 quarters · filed 2025-03-11 | $5.55M derived: sum of 3 quarters · filed 2025-03-11 | $8.01M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $863.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $5.62M derived: sum of 2 quarters · filed 2025-03-11 | $8.08M derived: sum of 3 quarters · filed 2025-03-11 | $10.63M 10-K · filed 2025-03-11 |
| 2022-09-30 | $4.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $7.22M derived: sum of 2 quarters · filed 2023-11-07 | $9.77M 10-Q · filed 2023-11-07 | $17.17M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $2.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $5.01M 10-Q · filed 2023-08-08 | $12.41M derived: sum of 3 quarters · filed 2024-02-28 | $11.88M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $2.56M 10-Q · filed 2023-05-04 | $9.95M derived: sum of 2 quarters · filed 2024-02-28 | $9.42M derived: sum of 3 quarters · filed 2024-02-28 | $402.92M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $7.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $6.87M derived: sum of 2 quarters · filed 2024-02-28 | $400.36M derived: sum of 3 quarters · filed 2024-02-28 | $401.24M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$531.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $392.96M derived: sum of 2 quarters · filed 2022-11-08 | $393.85M 10-Q · filed 2022-11-08 | $394.18M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $393.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $394.38M 10-Q · filed 2022-08-04 | $394.71M derived: sum of 3 quarters · filed 2023-02-28 | $394.75M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $884.00K 10-Q · filed 2022-05-10 | $1.22M derived: sum of 2 quarters · filed 2023-02-28 | $1.26M derived: sum of 3 quarters · filed 2023-02-28 | |
| 2020-12-31 | $338.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $373.00K derived: sum of 2 quarters · filed 2023-02-28 | $476.79M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $476.45M 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $476.42M 10-Q · filed 2021-08-12 | |||
| 2019-12-31 | $351.16M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |